Fenben cancer treatment is a drug that inhibits sugar uptake in cancer cells, thus depriving them of their primary fuel source. It has been shown to be effective against lymphoma tumors when used in combination with vitamins. The drug is also known to interfere with glucose metabolism and may have other effects on cancer cells. This drug has been in use as an anti-parasitic agent for a long time in the veterinary industry, but it is not yet approved for use against human diseases.
In a recent study, researchers found that the combination of a low-glycemic diet and fenbendazole caused significant tumor volume reduction in mice with lymphoma cell xenografts. They grouped the mice into groups that received either fenbendazole, vitamins, or both – and compared them to a control group that received only the anti-parasitic diet. Those treated with a vitamin-fenbendazole combination showed the most promising results, reducing their tumor volume by 48%.
To determine the reasons for this effect, researchers investigated several mechanisms. They observed that fenbendazole caused the expression of genes involved in glycolysis to be reduced, including hexokinase II and GLUT-4 transporter. In addition, the drug induced p53 activation and disruption of microtubules.
The researchers conclude that the results from the study indicate that fenbendazole may be an effective anti-cancer drug, but further research and substantial evidence are needed to support its use as an alternative cancer treatment for humans. The process of developing a new drug usually takes years, but repurposing veterinary drugs that show promising results could significantly reduce the time required to develop such medicines. fenben cancer treatment